Protalix BioTherapeutics Q1 2024 GAAP EPS $(0.06) Misses $(0.02) Estimate, Sales $3.748M Down From $9.588M YoY
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics reported a Q1 2024 GAAP EPS of $(0.06), missing the $(0.02) estimate, with sales of $3.748M, a decrease from $9.588M year-over-year.
May 10, 2024 | 10:53 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Protalix BioTherapeutics missed Q1 2024 earnings estimates with a GAAP EPS of $(0.06) and reported a significant decrease in sales year-over-year.
Missing earnings estimates and reporting a significant decrease in sales year-over-year are negative indicators that can lead to a decrease in investor confidence and potentially lower stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100